Oculis kynnir jákvæðar niðurstöður úr fasa 2b RELIEF-rannsókn með Licaminlimab, hannað til að umbylta meðferð augnþurrks með nákvæmnislyfjameðferð
June 10, 2024 05:00 ET
|
Oculis Holding AG
ZUG, Sviss, June 10, 2024 (GLOBE NEWSWIRE) -- Virkni lyfsins var greinileg með bætingu á mörgum teiknum (e. signs) augnþurrks í öllum rannsóknarhópnum ásamt því sem aukin áhrif sáust hjá hópi...
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
June 10, 2024 05:00 ET
|
Oculis Holding AG
ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1...
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
June 10, 2024 05:00 ET
|
Oculis Holding AG
Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1 genetic biomarker population as identified in prior...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
June 04, 2024 13:47 ET
|
Oculis Holding AG
ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the annual equity incentive awards granted to directors of the Company, as well as the one-time equity...
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
May 30, 2024 04:00 ET
|
Oculis Holding AG
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D....
Oculis birtir niðurstöður aðalfundar 2024 og tilkynnir um skipanir í stjórn og vísindaráð
May 30, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Sviss, May 30, 2024 (GLOBE NEWSWIRE) -- Hluthafar samþykktu alla dagskrárliði og tillögur stjórnarRobert K. Warner M.B.A. og Arshad M. Khanani M.D. M.A. FASRS kjörnir í stjórnBaruch D....
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
May 30, 2024 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) --Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS...
Oculis updates share capital for its existing at-the-market offering program
May 17, 2024 16:30 ET
|
Oculis Holding AG
ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the...
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
May 08, 2024 16:10 ET
|
Oculis Holding AG
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of...
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
May 08, 2024 16:10 ET
|
Oculis Holding AG
Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF...